The discovery broadens the known spectrum of this rare disorder, emphasizing the critical role of collaboration with patient ...

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) for chronic ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...

University of Chicago, Chicago, IL.

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with ...

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) for the treatment of chronic spontaneous ...

Schrödinger will report its first quarter 2025 financial results on Wednesday, May 7, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The ...

Field Medical Inc., a leader in cardiac pulsed field ablation (PFA) technology, announced today its FieldForcetm Ablation ...

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU) Approval based on Phase 3 trials demonstrating Dupixent ...

The approval was based on evidence from the CUPID clinical trial program (ClinicalTrials.gov Identifier: NCT04180488), which included 3 randomized, double-blind, placebo-controlled trials (CUPID Study ...

A new study reveals that cognitive changes tied to Alzheimer's risk factors begin far earlier in life than previously thought ...